NUVB.WS (Nuvation Bio) OCF Margin %: 6.09% (As of Mar. 2026)


NUVB.WS Nuvation Bio Inc NUVB.WS
33 GF Score
Price $0.01
! 3 Warning Signs
View Full Analysis

What is Nuvation Bio OCF Margin %?

Nuvation Bio NUVB.WS 33 OCF Margin % is 6.09% as of Mar. 2026. GuruFocus rates NUVB.WS with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Nuvation Bio ranks worse than 52.4% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Nuvation Bio's Cash Flow from Operations for the three months ended in Mar. 2026 was $5.07 Mil. Nuvation Bio's Revenue for the three months ended in Mar. 2026 was $83.23 Mil. Therefore, Nuvation Bio's OCF Margin % for the quarter that ended in Mar. 2026 was 6.09%.

As of today, Nuvation Bio's current OCF Yield % is -5.59%.

The historical rank and industry rank for Nuvation Bio's OCF Margin % or its related term are showing as below:


During the past 6 years, the highest OCF Margin % of Nuvation Bio was -275.71%. The lowest was -1656.46%. And the median was -966.09%.

NUVB.WS's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Nuvation Bio OCF Margin % Related Terms

Nuvation Bio OCF Margin % Historical Data

* Premium members only.

The historical data trend for Nuvation Bio's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvation Bio OCF Margin % Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -1,656.46 -275.71

Nuvation Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,382.20 -996.85 -403.12 -71.02 6.09
NUVB.WS
33GF Score
Nuvation Bio Inc NUVB.WS
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuvation Bio OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Nuvation Bio's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-173.427/62.902
=-275.71 %

Nuvation Bio's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=5.069/83.228
=6.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 6.09% mean?
Nuvation Bio (NUVB.WS) has a OCF Margin % of 6.09% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nuvation Bio and its competitors. According to the industry distribution chart, Nuvation Bio ranks #503 out of 960 companies in the Biotechnology industry, placing it in the top 52.4%.
Is Nuvation Bio's OCF Margin % too high?
Nuvation Bio's current OCF Margin % is 6.09%. Based on the distribution chart, Nuvation Bio ranks #503 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's OCF Margin % compare to GLUE and ATAI?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #503 out of 960 companies for OCF Margin %. This places Nuvation Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nuvation Bio and its competitors. Nuvation Bio's current OCF Margin % is 6.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB.WS) has a current OCF Margin % of 6.09%. The current OCF Margin % is 6.09%. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Nuvation Bio (NUVB.WS), the current OCF Margin % is 6.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvation Bio Business Description

Other Exchanges NUVB:USA
Address 1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score

Get the complete analysis for NUVB.WS

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price